WuXi Biologics (Cayman) Inc. (2269.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 119.42B |
| Enterprise Value | 113.3B |
| P/E Ratio | 27.99 |
| PEG Ratio | 0.6 |
| Price/Sales Ratio | 6.33 |
| Price/Book Ratio | 2.97 |
| Enterprise/Revenue | 6.05 |
| Enterprise/EBITDA | 16.65 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | December 31, 2025 |
Profitability
| Profit Margin | 0.23 |
| Operating Margin | 0.3 |
AD
Management Effectiveness
| Return On Assets | 0.08 |
| Return On Equity | 0.11 |
Income Statement
| Revenue | 21.79B |
| Revenue/Share | 5.17 |
| Gross Profit | 10.02B |
| EBITDA | 7.92B |
| Net Income | 4.91B |
| Diluted EPS | 1.16 |
Balance Sheet
| Total Cash | 15.74B |
| Total Cash/Share | 3.73 |
| Total Debt | 3.11B |
| Total Debt/Equity | 0.07 |
| Current Ratio | 3.14 |
| Book Value Per Share | 12.58 |
Price History
| 52-Week Change | 24.09 |
| 52-Week High | 44 |
| 52-Week Low | 28.48 |
| Moving Average 50 Days | 34.81 |
| Moving Average 200 Days | 35.12 |
Statistics
| Average Volume | 30.61M |
| Shares Outstanding | 4.14B |
| % Held by Institutions | 0.23 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 3:1 |
| Last Split Date | November 16, 2020 |
AD
